Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NUCALA Subcutaneous Injection Special Drug Use Investigation (EGPA, Long-term)

Trial Profile

NUCALA Subcutaneous Injection Special Drug Use Investigation (EGPA, Long-term)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2018

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Churg-Strauss syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Sep 2018 Status changed from recruiting to active, no longer recruiting.
    • 28 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 02 Jul 2018 Planned initiation date changed from 1 Jul 2018 to 25 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top